Company intelligence / Profile preview

LymeAlert

Cambridge/Boston area, Massachusetts, United Stateslymealert.com ↗

Ownership: Private
Development stage: Preclinical

Overview

LymeAlert is developing a rapid, home-based diagnostic kit for detecting the presence of Borrelia burgdorferi in ticks. The technology enables users to crush a tick, mix it with a proprietary solution, and use a lateral flow test strip to determine if the tick carries the bacteria responsible for Lyme disease. The product aims to enable earlier intervention and reduce unnecessary antibiotic use by providing results within 30 minutes after tick removal[1].

Therapeutic areas: Infectious Diseases
Modalities: DeviceDiagnostic test (lateral flow assay)
Industry: Protein Biomarker Diagnostics

Partnerships

MIT (startup affiliation)

Beyond the preview

Go deeper on LymeAlert.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LymeAlert.

Explore the full profile